ARTICLE | Clinical News
ABBV-8E12: Ph II started
February 1, 2017 10:14 PM UTC
AbbVie began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate IV ABBV-8E12 in about 180 patients. AbbVie has exclusive, worldwide rights to develop and commercialize the product fro...
BCIQ Target Profiles